Medical Spa Insider

This week, AmSpa CEO, Alex R. Thiersch, JD, speaks with Patrick O’Brien, JD, of AmSpa and ByrdAdatto, to discuss the legal concerns with compounded semaglutide and its name-brand drugs. They talk about the basic legal implications of Ozempic and recent lawsuits, compounding pharmacy issues and general guidelines for navigating this area of the law. Their conversation includes:

• How compounding pharmacies began compounding semaglutide;
• Patent protections for the name-brand manufacturer;
• Semaglutide salts and FDA warnings about base ingredients;
• The recent lawsuits and the issues at play;
• Trademarks, advertising and claims;
• How your medical spa can stay compliant when offering compounded semaglutide;
• And more!

Read more about the ongoing lawsuits filed by Novo Nordisk, maker of Ozempic and Wegovy, at the AmSpa Now blog. Stay tuned for new updates on the subject as more info becomes available.

This episode of Medical Spa Insider is sponsored by RepeatMD. Visit https://www.repeatmd.com/ to learn more!